WuXi PharmaTech's corporate venturing arm will merge with VC firm Frontline BioVentures to create an investment firm with $800m of assets under management.
WuXi Healthcare Ventures, the strategic investment arm of pharmaceutical research firm WuXi PharmaTech, has agreed to merge with venture capital firm Frontline BioVentures.
The merger will create a new entity called 6 Dimensions Capital which will have approximately RMB5.5bn ($800m) of assets under management. It intends to begin work raising dollar and renminbi-denominated funds soon.
WuXi Healthcare Ventures was launched in 2011 as a VC firm affiliated with WuXi PharmaTech, which is also known as WuXi AppTec. It had more…